These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17409841)

  • 21. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
    Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
    Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
    Azzoli CG; Krug LM; Miller VA; Rizvi NA; Kris MG; Dunne M; Farmer A; Pizzo B; Tyson L; Seeger T; Coleman B; Moore E; Lastinger L; Venkatraman E; Rudin CM
    J Thorac Oncol; 2007 Jul; 2(7):638-44. PubMed ID: 17607120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
    Lee JJ; Han JY; Lee DH; Kim HY; Chun JH; Lee HG; Yoon SM; Lee SY; Lee JS
    Jpn J Clin Oncol; 2006 Dec; 36(12):761-7. PubMed ID: 17043059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
    Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
    J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
    Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
    Masuda N; Negoro S; Kudoh S; Sugiura T; Nakagawa K; Saka H; Takada M; Niitani H; Fukuoka M
    J Clin Oncol; 2000 Aug; 18(16):2996-3003. PubMed ID: 10944133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
    Malik SM; Collins B; Pishvaian M; Ramzi P; Marshall J; Hwang J
    Clin Lung Cancer; 2011 Jul; 12(4):231-6. PubMed ID: 21726822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
    Lilenbaum R; Wang X; Gu L; Kirshner J; Lerro K; Vokes E
    J Clin Oncol; 2009 Sep; 27(27):4487-91. PubMed ID: 19704058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
    William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
    J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
    Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
    Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
    Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
    Lynch TJ; Fenton D; Hirsh V; Bodkin D; Middleman EL; Chiappori A; Halmos B; Favis R; Liu H; Trepicchio WL; Eton O; Shepherd FA
    J Thorac Oncol; 2009 Aug; 4(8):1002-9. PubMed ID: 19633475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
    Jalal S; Waterhouse D; Edelman MJ; Nattam S; Ansari R; Koneru K; Clark R; Richards A; Wu J; Yu M; Bottema B; White A; Hanna N
    J Thorac Oncol; 2009 Nov; 4(11):1420-4. PubMed ID: 19701110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.